Paper Details

  1. Home
  2. Paper Details

Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.

Author: AlexanderG Caleb, BakshSheriza N, McAdams-DeMarcoMara, SegalJodi B

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Reports to the FDA Adverse Event Reporting System suggest a possible increased risk of heart failure associated with dipeptidyl peptidase-4 inhibitors, but more research is needed.
Paper Details　
Original Abstract of the Article :
In 2008, the US Food and Drug Administration (FDA) issued Draft Guidance on investigating cardiovascular risk with oral diabetic drugs, including dipeptidyl peptidase-4 inhibitors (DPP-4i). In 2014, underpowered, post hoc analyses of clinical trials suggested an increased risk of heart failure with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/29655237

データ提供：米国国立医学図書館（NLM）

Cardiovascular Safety Signals with DPP-4 Inhibitors: A Disproportionality Analysis

Dipeptidyl peptidase-4 inhibitors (DPP-4i), a class of drugs used to manage type 2 diabetes, have been under scrutiny regarding their potential cardiovascular risks. This research aims to analyze the safety signals associated with DPP-4i, specifically focusing on major adverse cardiac events (MACE) reported to the FDA Adverse Event Reporting System (FAERS).

A Close Examination of DPP-4i: Navigating the Cardiovascular Landscape

The study analyzed data from FAERS, examining the frequency of MACE reports associated with DPP-4i use. The findings suggest a potential disproportionate reporting of MACE among DPP-4i users, raising concerns about cardiovascular safety. Imagine navigating a desert with a faulty compass – the potential for unexpected risks is high. This research provides valuable insights into the potential risks associated with DPP-4i use.

Navigating the Desert of Cardiovascular Risks: Cautious Approach

This research highlights the importance of carefully considering the potential cardiovascular risks associated with DPP-4i use. It underscores the need for ongoing monitoring and vigilant attention to patient safety. Like navigating a desert, we need to proceed with caution, understanding the potential pitfalls and taking necessary precautions.

Dr.Camel's Conclusion

This research on DPP-4i and cardiovascular safety serves as a reminder that even in the vast desert of medical knowledge, surprises can lurk. The findings highlight the importance of continuous vigilance and careful monitoring to ensure patient safety. It encourages us to approach drug use with a cautious and informed mindset, weighing the benefits against the potential risks.

Date :
  1. Date Completed 2019-09-16
  2. Date Revised 2021-07-01
Further Info :

Pubmed ID

29655237

DOI: Digital Object Identifier

NIHMS1047658

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.